The conversation will focus on the key benefits and concerns of FDA virtual inspections versus the current traditional physical inspections.

The panel will specifically address:

• Pros, cons, and readiness considerations for the prospect of virtual FDA inspections;
• Legal authority and constraints on FDA conduct and information requests;
• How to effectively prepare for a remote FDA inspection; and
• Special considerations and risks with information sharing in a virtual context.

The panel discussion will include sufficient time to address questions from the audience, and we’d love if you could join us on the 26th.